Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to gather information regarding the use of Myfortic, Prograf,
and corticosteroids in new liver transplant recipients. These three medicines help to prevent
the body from rejecting the transplanted liver. The information the investigators are
obtaining is data relating to the process of Myfortic absorption by the body, its
distribution in the body, the breakdown of Myfortic in the body, and its elimination from the
body. This absorption, distribution, breakdown, and elimination is called pharmacokinetics.